AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update - PubMed
3 hours ago
- #MASH
- #Pharmacological Treatment
- #MASLD
- MASLD is now the leading cause of chronic liver disease globally, surpassing viral hepatitis.
- Prevalence of MASLD is increasing in Italy, especially among individuals with type 2 diabetes, obesity, and metabolic syndrome.
- Progression from steatosis to MASH and advanced fibrosis increases risks of cirrhosis, hepatocellular carcinoma, and cardiovascular mortality.
- FDA and EMA have approved Resmetirom and Semaglutide, the first drugs showing histological efficacy in Phase 3 trials for MASH with F2-F3 fibrosis.
- The AISF STEPS-MASH framework provides a structured approach for identifying, selecting, and monitoring patients eligible for therapy.
- The position paper offers evidence-based recommendations for integrating new pharmacological treatments into clinical practice in Italy.